Prostate cancer: preventing metastasis to bone: is this the end of the story?
A new report of zoledronic acid in men with high-risk prostate cancer is the latest in a long line of negative studies that have addressed the prevention of metastasis. We must learn from these studies so that potentially useful agents are not discarded due to poor trial design in the future.